Effects pf combined administration of 5-HT1A and/or 5-HT1B receptor antagonists and paroxetine or fluoxetine in the forced swimming test in rats

Polish Journal of Pharmacology

Volumn 54, Issue 6, 2002, Pages 615-623

  Tatarczyńska, Ewa ^a   Kłodzińska, Aleksandra ^a   Chojnacka Wójcik, Ewa ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT1A 5 HT1B antagonists; Fluoxetine; Forced swimming test; Paroxetine; Rats

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [3 (2 DIMETHYLAMINO)ETHOXY 4 METHOXYPHENYL] 2' METHYL 4' [5 METHYL 1,2,4 OXADIOL 3 YL] [1,1' BIPHENYL] 4 CARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; PAROXETINE; PINDOLOL; SB 216641; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; WAY 100365; SEROTONIN 1 RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; FORCED SWIMMING TEST; IMMOBILIZATION; LOCOMOTION; NONHUMAN; OPEN FIELD BEHAVIOR; RAT; RECEPTOR BLOCKING; ANIMAL; DRUG COMBINATION; MALE; PHYSIOLOGY; SWIMMING; WISTAR RAT;

ANIMALS; DEPRESSION; DRUG THERAPY, COMBINATION; FLUOXETINE; IMMOBILIZATION; MALE; PAROXETINE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN ANTAGONISTS; SWIMMING;

EID: 0036968608     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. 1A receptor agonist properties of (-)pindolol in combination with citalopram on serotoninergic dorsal raphe cell firing in vivo. Psychopharmacology, 2000, 151, 77-84.
2. Artigas F., Perez V., Alvarez E.: Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiat., 1994, 51, 248-251.
3. 1A antagonists. Trends Neurosci., 1996, 19, 378-383.
4. Berman R.M., Anand A., Cappiello A., Miller H.L., Hu X.S., Oren D.A., Charney D.S.: The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol. Psychiat., 1999, 45, 1170-1177.
5. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S.: Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Amer. J. Psychiat., 1997, 154, 37-43.
6. Blier P., Bergeron R.: Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol., 1995, 15, 217-222.
7. 1A receptors induces rapid antidepressant response. Neuropsychopharmacology, 1997, 16, 333-338.
8. 1B receptors. J. Pharmacol. Exp. Ther., 1989, 250, 37-43.
9. Borsini F.: Role of the serotonergic; system in the forced swimming test. Neurosci. Biobehav. Rev., 1995, 19, 377-395.
10. Borsini F., Meli A.: Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology, 1988, 94, 147-160.
11. 1F receptor messenger RNA in rodent and primate brain. Neuropharmacology, 1994, 33, 367-386.
12. 1A autoreceptors in vivo. Brit. J. Pharmacol., 1998, 124, 206-212.
13. Cousins M.S., Seiden L.S.: The serotonin-1A receptor antagonist WAY-100635 modifies fluoxetine's antidepressant-like profile on the differential reinforcement of low rates 72-s schedule in rats. Psychopharmacology, 2000, 148, 438-442.
14. Cryan J.F., McGrath C., Leonard B.E., Norman T.R.: Combining pindolol and paroxetine in an animal model of chronic antidepressant action - can early onset of action be detected? Eur. J. Pharmacol., 1998, 352, 23-28.
15. 1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat. Pharmacol. Biochem. Behav., 1999, 63, 333-338.
16. Da-Rocha M.A. Jr., Puech A.J., Thiébot M.H.: Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice. J. Pharmacol., 1997, 11, 211-218.
17. 1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur. J. Pharmacol., 1998, 345, 41-46.
18. Detke M.J., Rickels M., Lucki I.: Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology, 1995, 121, 66-72.
19. Dinan T.G., Scott L.V: Does pindolol induce a rapid improvement in depressed patients resistant to serotonin reuptake inhibitors? J. Ser. Res., 1996, 3, 119-121.
20. 1B knockout mice. Eur. J. Neurosci., 2000, 11, 3823-3831.
21. Forster E.A., Cliffe I.A., Bill D.J., Dover G.M., Jones D., Reilly Y., Fletcher A.: A pharmacological profile of the selective silent 5-HT-1A receptor antagonist, WAY-100635. Eur. J. Pharmacol., 1995, 281, 81-88.
22. 1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam. Clin. Pharmacol., 1996, 10, 16-27.
23. 1B auto- and heteroreceptors in the mechanism of action of selective serotonin reuptake inhibitors in mice. Eur. Neuropsychopharmacol., 2001, 11, Suppl. 3, S208.
24. 1A receptor antagonists in three rat models of anxiety. Neuropharmacology, 2000, 39, 1848-1857.
25. 1B receptors causes hypothermia in the guinea pig. Eur. J. Pharmacol., 1997, 331, 169-174.
26. Hervas Queiroz C.M.T., Adell A., Artigas F.: Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Brit. J. Pharmacol., 2000, 130, 160-166.
27. 1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav. Brain. Res., 1996, 73, 281-283.
28. Hjorth S., Bengtsson H.J., Kullberg A., Carlzon D., Peilot H., Auerbach S.B.: Serotonin autoreceptor function and antidepressant drug action. J. Psychopharmacol., 2000, 14, 177-185.
29. Hjorth S., Carlsson A.: Is pindolol a mixed agonist - antagonist at central serotonin (5-HT) receptors? Eur. J. Pharmacol., 1986, 129, 131-138.
30. Hyttel J.: Experimental pharmacology of selective 5-HT reuptake inhibitors: differences and similarities. Clin. Neuropharmacol., 1984, 7, Suppl. 1, S466.
31. Hyttel J.: Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol., 1994, 9, Suppl. 1, 19-26.
32. Janssen P.A.J., Jagenau A.H.M., Schellekens K.H.C.: Chemistry and pharmacology of compound related to 4-(4-hydroxy-4-phenylpiperidino)-butyrophenone. IV. Influence of haloperidol (R-1625) and chloropromazine on the behaviour of rats in a unfamiliar open fleld situation. Psychopharmacologia (Berlin), 1960, 1, 389-392.
33. 1B receptor stimulation in the rat elevated plus-maze. Pharmacol. Biochem. Behav., 2002, 71, 581-587.
34. Lucki I.: 5-HT1 receptors and behavior. Neurosci. Biobehav. Rev., 1992, 16, 83-89.
35. 1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Neuropsychopharmacology, 1999, 21, 61-67.
36. 1B/D receptors in psychiatric disorders and their potential as a target for therapy. Eur. J. Pharmacol., 2000, 404, 1-12.
37. 1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats. Eur. J. Pharmacol., 1999, 372, 127-134.
38. O'Neill M.F., Fernández; A.G., Palacios J.M.: GR 127935 blocks the locomotor and antidepressant-like effects of RU 24969 and the action of antidepressants in the mouse tail suspension test. Pharmacol. Biochem. Behav., 1996, 53, 535-539.
39. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F.: Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet, 1997, 349, 1594-1597.
40. Porsolt R.D., Anton G., Blavet N., Jalfre M.: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol., 1978, 47, 379-391.
41. Porsolt R.D., Bertin A., Blavet N., Daniel M., Jalfre M.: Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur. J. Pharmacol., 1979, 57, 201-210.
42. 1B receptors in the sensitization to amphetamine in mice. Eur. J. Pharmacol., 2001, 422, 91-99.
43. 1A) receptors in the anticonflict activity of β-adrenoceptor antagonists. Neuropharmacology, 1995, 34, 1211-1217.
44. Redrobe J.P., Bourin M., Colombel M.C., Baker G.B.: Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms. J. Psychopharmacol., 1998, 12, 348-355.
45. 1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur. J. Pharmacol., 1996, 318, 213-220.
46. 1A receptors are critically involved in the anxiolytic effects of 8-OH-DPAT. Psychopharmacology, 1996, 125, 89-91.
47. Sacristan J.A., Gilaberte I., Boto B., Buesching D.P., Obenchain R.L., Demitrack M., Sola V.P., Alvarez E., Artigas F.: Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial. Int. Clin. Psychopharmacol., 2000, 15, 107-113.
48. 3H]dopamine from rat striatal synaptosomes. Naunyn-Schmied. Arch. Pharmacol., 1999, 359, 40-47.
49. 1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors. Naunyn-Schmied. Arch. Pharmacol., 1997, 356, 321-327.
50. 1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Brit. J. Pharmacol., 1989, 96, 283-290.
51. 1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Brit. J. Pharmacol., 1997, 121, 941-946.
52. 1D receptor antagonist GR127935 on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysis. Neuropharmacology, 1995, 34, 377-382.
53. Słuzewska. A., Szczawińska K.: The effects of pindolol addition to fluvoxamine and buspirone in chronic mild stress model of depression. Behav. Pharmacol., 1996, 7, Suppl. 1, 105.
54. 1A autoreceptors modulate 5-HT release in the guinea-pig dorsal raphé nucleus. Neuropharmacology, 1994, 33, 393-402.
55. 1B selective antagonist with antidepressant potential. Eur. Neuropsychopharmacol., 2001, 11, Suppl. 3, S178.
56. Thase M.E., Rush A.J.: Treatment-resistant depression. In: Psychopharmacology: The Fourth Generation of Progress. Eds.: Bloom F.E., Kupfer D.J., Raven Press, New York, 1995, 1081-1097.
57. Tome M.B., Isaac M.T., Harte R., Holland C.: Paroxetine and pindolol: a randomised trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int. Clin. Psychopharmacol., 1997, 12, 81-89.
58. 1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-N-propylamino)tetralin in the rat. Eur. J. Pharmacol.,